ERBB2 and glioblastoma: The observed amplifications complied with clinical specifications and additional molecular findings [28–33]: we detected an EGFR amplification in four samples (i.e. three EGFR-mutated lung tumors and one glioblastoma specimen), a BRAF amplification in two samples (both BRAF-mutated melanoma samples), a PIK3CA amplification in one sample (EGFR-mutated NSCLC case that showed progression upon tyrosine kinase inhibitor treatment), a KRAS amplification in one sample (NSCLC case without any identified mutations), and an ERBB2 (HER2) amplification in one sample (salivary duct carcinoma).